SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–TeraPore Technologies, the developer of advanced nanofiltration membrane systems for biomanufacturing, today announced it has raised $10M in new financing. The round was led by existing investor Anzu Partners with participation from Entegris (NASDAQ: ENTG), a global leader in advanced materials science, and fellow existing investor, RA Capital Management. TeraPore will leverage the funding to launch its IsoBlock™ virus filter and expand the use of its core technology into new high value markets.

“We are glad to have the continued support of Anzu Partners and RA Capital Management and are excited to welcome Entegris as a new investor. Entegris brings deep technical expertise and can help accelerate the deployment of our technology into new contamination control applications.”

Tweet this

TeraPore is developing a new generation of high-capacity, high-yield bioseparation solutions that enable controllable, consistent purification processes for the manufacturing of novel therapeutics and biologics. Unlike conventional filter technology, IsoBlock virus filters leverage TeraPore’s Intelligent Membrane™ platform, which features a tunable chemical structure and uniform nanoscale pore sizes that can tackle the most difficult separation challenges.

The IsoBlock virus filters are highly engineered from the ground up to provide superior filter productivity and robust viral clearance during process development, clinical trials, and production scale manufacturing. The company is developing a family of IsoBlock filters with various properties and device sizes.

“As the pipeline for new biologics continues to rapidly increase, so does the need for more powerful and precise filtration technologies like ours that can improve the manufacturing process,” said Dr. Rachel Dorin, CEO and Co-Founder of TeraPore Technologies. “We are glad to have the continued support of Anzu Partners and RA Capital Management and are excited to welcome Entegris as a new investor. Entegris brings deep technical expertise and can help accelerate the deployment of our technology into new contamination control applications.”

“We are pleased to contribute to the development of TeraPore as it enters the critical commercialization phase for their highly differentiated Intelligent Membrane platform,” said Olivier Blachier, senior vice president at Entegris. “We believe that this technology has a high potential to also address important nanofiltration challenges in a number of applications.”

Olivier Blachier, who leads business and new market development for Entegris, will also join the TeraPore Board of Directors along with Mani Krishnan, a seasoned expert in the filtration and biotechnology sector who held leadership roles at Millipore Sigma and Pall Corporation.

For more information about TeraPore Technologies, please visit https://www.terapore.com/.

About TeraPore Technologies

TeraPore Technologies develops high-permeability, high-resolution membrane nanofiltration systems for bioprocessing and other applications. Its mission is to solve the most challenging bioseparation problems. TeraPore is a venture-backed firm whose key investors include Anzu Partners, Artiman Ventures, RA Capital Management, Entegris, and the law firm of Wilson Sonsini. TeraPore has also been the recipient of grant funding from the National Science Foundation, the National Institutes of Health (NIH), and the Defense Threat Reduction Agency. For more information, visit www.terapore.com.

About Entegris

Entegris is a world-class supplier of advanced materials and process solutions for the semiconductor and other high-tech industries. Entegris has approximately 10,000 employees throughout its global operations and is ISO 9001 certified. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, France, Germany, Israel, Italy, Japan, Malaysia, Singapore, South Korea, United Kingdom, and Taiwan. Additional information can be found at www.entegris.com.

About Anzu Partners

Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep expertise in business development, market positioning, intellectual property, global connectivity, and operations. For more information, please visit https://anzupartners.com/.

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization. For more information, please visit www.racap.com.